In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 634 ( 2022-03-02)
Kurzfassung:
Understanding how antibodies elicited by SARS-CoV-2 infection or vaccination respond to variants of concern is essential, particularly as the Omicron variant becomes dominant globally. Here, Sievers et al. tested the capacity of serum or plasma from individuals infected with or vaccinated against SARS-CoV-2 to neutralize pseudoviruses expressing spike proteins from wild-type (D614) SARS-CoV-2 or from the Beta, Delta, and Omicron variants of concern. To do so, they studied three cohorts: individuals infected with SARS-CoV-2, pregnant individuals who received two doses of mRNA vaccine, and health care workers who received two doses of mRNA vaccine plus a booster dose. The authors consistently found poorer neutralization of Beta and Omicron spike protein–expressing pseudoviruses, though boosting improved neutralization activity. These findings support the administration of booster vaccines and add to our understanding the degree to which the Omicron variant evades immune responses.
Materialart:
Online-Ressource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abn7842
Sprache:
Englisch
Verlag:
American Association for the Advancement of Science (AAAS)
Publikationsdatum:
2022